



NDA 21-821/S-043

**SUPPLEMENT APPROVAL**

Pfizer, Inc.  
Attention: Nadia D. Kirzecky  
Director, Worldwide Safety and Regulatory  
235 East 42<sup>nd</sup> Street  
New York, NY 10017

Dear Ms. Kirzecky:

Please refer to your Supplemental New Drug Application (sNDA) dated December 9, 2015, received December 9, 2015, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Tyagcil (tigecycline) Injection.

This “**Prior Approval**” supplemental new drug application provides for revisions to several sections of the labeling to be consistent with the Physicians Labeling Rule (PLR) and revisions to the **INDICATIONS AND USAGE** Section, **Community-Acquired Bacterial Pneumonia** subsection (**1.3**), **OVERDOSAGE** section (**10**), and the **CLINICAL PHARMACOLOGY**, Section, **Microbiology** Subsection (**12.4**).

**APPROVAL & LABELING**

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text and with the minor editorial revisions for the **INDICATIONS and USAGE** Section and the **Microbiology** subsection (12.4) listed below and indicated in the enclosed labeling.

1. The qualifier (beta-lactamase-negative isolates) that is associated with *H. influenzae* be removed from the indications and from the list of organisms in the Microbiology section.
2. One of the footnotes on anaerobic techniques (4) is missing after the word “method”. This references CLSI M100.
3. In the Susceptible, Intermediate, Resistant definitions delete the “s” in the word “concentrations”. This word is used in the definition for Susceptible and also Resistant.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to, except with the revisions listed and indicated, the enclosed

labeling text for the package insert with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes with the revisions listed and indicated above approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Carmen DeBellas, Regulatory Project Manager, at (301) 796-1203.

Sincerely,

*{See appended electronic signature page}*

Sumathi Nambiar, MD, MPH  
Director  
Division of Anti-Infective Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

SUMATHI NAMBIAR  
01/19/2016